Evaluation of kisspeptin levels in obese pregnancy as a biomarker for pre‐eclampsia

摘要: Summary Objectives  Circulating concentrations of the peptide kisspeptin have been proposed as a novel biomarker for early detection pre-eclampsia. Our aims were to assess analytical and clinical performance characteristics commercial assay determine sensitivity specificity test pre-eclampsia. Design  Prospective, longitudinal study in United Kingdom tertiary referral Antenatal Metabolic Clinic. Patients  Severely obese (body mass index, BMI > 40kg/m2, n = 194) lean (BMI < 25kg/m2, n = 78) pregnant women. Measurements  A ELISA (Phoenix Pharmaceuticals) was assessed sensitivity, specificity, precision, linearity, recovery stability maternal plasma samples at 16, 28 36 weeks gestation. Pre-eclampsia, defined using International Society Study Hypertension Pregnancy guidelines; blood pressure; delivery gestation; birthweight. Results  Kisspeptin lower pregnancy women (P < 0·001), who later developed pre-eclampsia (P < 0·05), compared with uncomplicated pregnancies. For 16-week prediction pre-eclampsia, area under receiver-operator characteristic curve 0·80 (P < 0·01), positive negative likelihood ratios 3·0 0·2, 85·7 71·4%, respectively. In regression analyses, (16 weeks) associated positively gestation (P < 0·05) birthweight (P < 0·0001), negatively 28- 36-week pressure (P < 0·0001). Conclusions  concentration is promising low but cannot be recommended, isolation, universal screening because inadequate specificity. Large-scale studies are required its potential panel biomarkers.